Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …

Increased recruitment of transitional and non-classical monocytes in the lung during SARS-
CoV-2 infection is associated with COVID-19 severity. However, whether specific innate …

The COVID-19 pandemic has plagued the world for over three years since discovering the
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …

Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), may be complicated by life-threatening interstitial pneumonia …

Purpose The COVID-19 pandemic has been a dramatic trigger that has challenged the
intrinsic capacity of older adults and of society. Due to the consequences for the older …

The scientific and medical community faced an unprecedented global health hazard that led
to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory …

ABSTRACT Introduction Nirmatrelvir/ritonavir (Paxlovid®) represent an oral antiviral therapy
approved for the treatment of COVID-19. Extensive in vitro and in vivo studies have reported …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to
affect vessels and nerves and can be easily visualized in the retina. However, the effect of …

The possible future emergence of new SARS-CoV-2 virus variants pushes the development
of new chemoprophylaxis protocols complementary to the unspecific and specific immune …